Company looks to advance polymer technologies as it meets key milestones set by Department of Defense’s Defense Advanced Research Projects Agency (DARPA) program.
CytoSorbents Corp., a company using blood purification technology to treat life-threatening illnesses, today announced that it has received from DARPA a technology development contract worth up to $3.8 million as part of its Dialysis-Like Therapeutics (DLT) program to treat sepsis, an often fatal condition caused by microorganisms or toxins in the tissue or bloodstream.
DARPA, an agency of the U.S. Department of Defense, is funding CytoSorbents’ development of a portable, artificially intelligent blood purification system capable of detecting and removing substances that can contribute to sepsis, including cytokines, toxins, biowarfare agents, pathogens, and activated cells.
Per the new development contract, CytoSorbents will receive $1.5 million in funding designated for the first of five years, based upon the satisfactory achievement of pre-determined milestones.
“We are delighted to officially begin working with DARPA on this exciting project and are honored to have had our unique core blood purification technology selected for funding. We are one of the industry leaders in the area of blood purification to treat sepsis and other critical care illnesses, with our first-in-class CytoSorb cytokine filter currently approved and commercialized in the European Union,” Dr. Phillip Chan, CEO, stated in the press release.
“That being said, under this DARPA program, we are looking to significantly advance our polymer technologies to not only remove cytokines, but also a wide variety of toxins, and do so with little to no anti-coagulation in both high flow and microfluidic systems. …”
Dr. Chan praised CytoSorbents’ technology and voiced assurance that the company can meet DARPA’s requirements.
“Because of the maturity of our technology, we are confident in our ability to meet DARPA’s timetable for technology development and strict performance metrics. Over the past several months, we have also collaborated with some of the leading potential systems integrators, to include our technologies into their integration proposals, under a separately funded DARPA DLT solicitation. The role of the systems integrator is to put together the best detection, separation and predictive modeling technologies into a single blood purification system and guide it to human clinical trials within 4 to 5 years. These partnerships are mutually beneficial and will help to contribute to the success of the overall program,” he stated.
There are currently no approved therapies to treat sepsis in the U.S. or in the EU.
For more information visit www.cytosorbents.com
Let us hear your thoughts below: